(Q37145171)

18 August 2017

1 reference

title

Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy (English)

1 reference

18 August 2017

0 references

1 reference

2

Meredith Regan

1 reference

18 August 2017

1

Sabina Signoretti

1 reference

18 August 2017

Michael Atkins

3

1 reference

18 August 2017

1 June 2008

1 reference

18 August 2017

1 reference

18 August 2017

101 Suppl 4

1 reference

18 August 2017

31-35

1 reference

Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience.

18 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07646.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07646.X

The genetic basis of cancer of kidney cancer: implications for gene-specific clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07646.X

Genetic basis of cancer of the kidney: disease-specific approaches to therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07646.X

21 January 2018

Focus on kidney cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07646.X

Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07646.X

Systemic therapy for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07646.X

Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07646.X

Emerging drugs for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07646.X

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07646.X

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07646.X

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07646.X

Role of VHL gene mutation in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07646.X

Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07646.X

Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07646.X

Ras, PI(3)K and mTOR signalling controls tumour cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07646.X

Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07646.X

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07646.X

Renal-cell carcinoma--molecular pathways and therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07646.X

The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07646.X

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07646.X

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07646.X

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07646.X

Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07646.X

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07646.X

Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07646.X

10.1111/J.1464-410X.2008.07646.X

21 January 2018

Identifiers

DOI

1 reference

release_vnxnqwzm3rh6rh7vwfsvbbux7m

18 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vnxnqwzm3rh6rh7vwfsvbbux7m

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

18430120

1 reference

PubMed ID

18430120